|
|
Comparative Study of Preoperative Systemic Intravenous Chemotherapy and Transcatheter Arterial Embolization Chemotherapy in Children with Nephroblastoma |
LIU Yu, HE Jun, He Tian-qu, et al |
Department of Urology, Hunan Children's Hospital,Changsha 410007, China |
|
|
Abstract 【Objective】 To compare and analyze the effect of preoperative systemic venous chemotherapy and transcatheter arterial embolization chemotherapy on nephroblastoma in children. 【Methods】 Children with nephroblastoma admitted to our hospital from January 2010 to December 2019 were selected retrospectively as the study objects. Among them, 48 cases received preoperative chemotherapy by transcranial arterial embolization as the observation group, and 33 cases received systemic intravenous chemotherapy as the control group. The tumor volume reduction rate, tumor necrosis rate, capsule integrity rate, overall effective rate of preoperative chemotherapy, total tumor resection rate, 2-year tumor-free survival rate and adverse reactions were observed and compared in the two groups. 【Results】 Tumor volume reduction rate, tumor necrosis rate, capsule integrity rate, overall effective rate of preoperative chemotherapy and total tumor resection rate were all higher in the observation group than in the control group, and the incidence of adverse reactions was lower than that in the control group, with statistically significant differences (P<0.05).The 2-year tumor-free survival rate in the control group (94%) was higher than that in the observation group (88%), but the difference was not statistically significant (P<0.05). 【Conclusion】 Compared to systemic intravenous chemotherapy, preoperative transcranial arterial embolization is more beneficial to surgical resection, with higher efficacy and fewer adverse reactions in children with nephroblastoma. However, it does not show a better advantage in 2-year tumor-free survival rate, so it is necessary to further expand the sample size and follow up time for clinical study.
|
Received: 03 November 2020
|
|
|
|
|
[1] 王艳君,李旭良.术前化疗在肾母细胞瘤治疗中的应用及价值[J].临床小儿外科杂志,2015,14(4):324-327.
[2] Nakamura L,Ritchey M.Current management of wilms ' tumor[J].Curr Urol Rep,2010,11(1):58-65.
[3] 曹嫣娜,王平,张广超 .36 例儿童肾母细胞瘤综合治理的临床探讨[J].中国肿瘤临床, 2008, 35(7):366-368.
[4] 孙洁,汤静燕. 儿童肾母细胞瘤的诊断治疗进展[J].中国小儿血液与肿瘤杂志, 2007, 12(1) :41-45.
[5] 孙志南,胡东来,黄益平,等.术前经动脉化疗栓塞治疗婴儿肾母细胞瘤的疗效观察[J].浙江医学,2016,38(2):105-108.
[6] 贾绚,赖灿,潘海鹏,等.儿童中晚期肾母细胞瘤术前经肾动脉栓塞化疗的疗效对比评价[J].中华医学杂志,2019(15):1147-1151.
[7] 董淳强,杨体泉,罗意革.术前不同化疗模式对肾母细胞瘤VEGF表达的影响及其与预后的关系[J].广西医学,2009,31(10):1415-1417.
[8] Li MJ,Zhou YB,Huang Y,et al.A retrospective study of the preoperative treatment of advanced Wilms tumor in children with chemotherapy versus transcatheter arterial chemoembolization alone or combined with short-term systemic chemotherapy[J].J Vasc Interv Radiol,2011,22(3): 279-286. |
|
|
|